Table 1 Details of the data sources used in this study
Phenotype | Abre. | Traits | Source | Sample size Total (cases/ controls) | Ancestry | Reference |
|---|---|---|---|---|---|---|
Diabetes Phenotypes & Glycemic Traits | ||||||
Type 1 diabetes | T1DM | Type 1 diabetes | NA | 520,580 (18,942/501,638) | European | Chiou et al. [14] |
Type 2 diabetes | T2DM | Type 2 diabetes | NA | 933,970 (80,154/853,816) | European | Mahajan et al. [15] |
Glycated hemoglobin levels | HbA1c | Glucose tolerance test | MAGIC | 146,806 | European | Chen et al. [17] |
Fasting glucose | FG | Glucose tolerance test | MAGIC | 200,622 | European | Chen et al. [17] |
Two-hour glucose | 2hGlu | Glucose tolerance test | MAGIC | 63,396 | European | Chen et al. [17] |
Insulin fold change during an oral glucose tolerance test (adjusted for BMI) | IFC | Insulin resistance | MAGIC | 53,287 | European | Williamson et al. [16] |
Modified Stumvoll Insulin Sensitivity Index (adjusted for BMI) | ISI | Insulin resistance | MAGIC | 53,657 | European | Williamson et al. [16] |
Fasting insulin | FI | Pancreatic β-cell dysfunction | MAGIC | 151,013 | European | Chen et al. [17] |
Proinsulin | PROI | Pancreatic β-cell dysfunction | MAGIC | 45,861 | European | Broadaway et al. [18] |
Parkinson’s disease phenotypes | ||||||
Parkinson’s disease risk | PD risk | PD risk | IPDGC | 482,730 (33,674/449,056) | European | Nalls et al. [20] |
Age at onset of Parkinson’s disease | AAO | PD prodrome | IPDGC | 28,568 | European | Blauwendraat et al. [19] |
UPDRS3 | NA | PD progression | IPDGC | 4093 | European | Iwaki et al. [21] |
MMSE | NA | PD progression | IPDGC | 4093 | European | Iwaki et al. [21] |
MOCA | NA | PD progression | IPDGC | 4093 | European | Iwaki et al. [21] |
Anti-diabetic drugs phenotypes | ||||||
Drugs used in diabetes | NA | Antidiabetic drugs | UK Biobank | 305,913 (15,272/290,641) | European | Wu et al. [23] |
Diabetes, insulin treatment | NA | Anti-diabetic drugs | FinnGen | 218,792 (29,071/189,721) | European | Kurki et al. [24] |
Metformin | NA | Anti-diabetic drugs | FinnGen | 462,933 (11,552/451,381) | European | Kurki et al. [24] |